GlassScriptPhysician profile
Parminder P Singh
NPI 1568512036
$14,260.49
in general payments reported to CMS, 2019-2025
53 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,678 · 2020: $1,661 · 2021: $1,580 · 2022: $3,123 · 2023: $1,995 · 2024: $1,705 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,219.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,178.70 | 2019-2025 | |
| Boston Scientific Corporation | $1,293.05 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Amgen INC. | $988.45 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $934.87 | 2019-2024 | Jardiance |
| Edwards Lifesciences Corporation | $824.85 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $661.85 | 2020-2025 | Impella |
| Pfizer INC. | $651.54 | 2019-2025 | |
| Novo Nordisk INC | $583.38 | 2019-2025 | Wegovy, Ozempic |
| Biotronik INC. | $477.23 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $418.48 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $380.81 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $359.23 | 2019-2025 | Farxiga |
| Inari Medical, INC. | $326.17 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $320.45 | 2019-2023 | Aveir |
| Medtronic, INC. | $306.13 | 2021-2024 | Micra, Corevalve Evolut R, Azure Xt Dr Mri Surescan |
Show all 51 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parminder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.